Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) reported robust outcomes for the second quarter of 2024 and once more revised its forecast upwards.
The corporate reported second quarter income of $4.2 billion, up 7% from the corresponding quarter of 2023. GAAP internet loss within the second quarter was $846 million ($0.75 per share) in contrast with GAAP internet lack of $872 million ($0.78 per share) within the second quarter of 2023. Non-GAAP internet revenue was $697 million ($0.61 per share) $0.61 in contrast with $629 million ($0.56 per share) within the second quarter of 2023.
RELATED ARTICLES
Teva agrees $750m Israel Tax Authority settlement
Teva once more king of Tel Aviv fort
Teva schizophrenia drug Part III outcomes excite analysts
Teva hits five-year excessive after Q1 outcomes
After a robust first half of 2024, Teva feels assured sufficient to boost its 2024 income forecast to $16-16.4 billion, up from $15.7-16.3 billion. $1.6 billion is predicted to come back from gross sales of branded drug Austedo, which treats tardive dyskinesia and Huntington’s illness chorea, up 2.5% from 2023. Teva sees EBITDA of $4.6-5 billion in 2024, up from $4.5-5 billion and raised its non-GAAP revenue forecast from $2.2-2.5 billion to $2.3-2.5 billion.
Teva returned to progress in 2023 after 5 years of falling income.
Teva’s President and CEO Richard Francis stated, “Within the second quarter of 2024, we’re inspired by the optimistic momentum throughout every of the 4 pillars of our Pivot to Development technique. Teva’s international revenues of $4.2 billion elevated by 7% in U.S. {dollars}, or 11% in native forex phrases in comparison with the second quarter of 2023, delivering robust progress pushed primarily by our generics and revolutionary enterprise, with AUSTEDO rising 32% within the US in comparison with Q2 2023.”
He added, “We’re additionally displaying important progress in on our late-stage revolutionary pipeline, underscored by the acceleration of the event timeline of duvakitug (Anti-TL1A), with top-line outcomes now anticipated within the fourth quarter of 2024, and full information anticipated subsequent 12 months.”
Teva’s share worth has risen 57% for the reason that begin of the 12 months and closed final evening on Wall Avenue with a market cap of $18.9 billion.
Replace: The corporate’s share worth is up 5.76% on the NYSE at the moment.
Printed by Globes, Israel enterprise information – en.globes.co.il – on July 31, 2024.
© Copyright of Globes Writer Itonut (1983) Ltd., 2024.
